I didn't say PYC will have the decision - just that Genentech will have made theirs. Agree with your last line which is what seems to have caused so much angst in some shareholders about PYC letting info fizzle - the reality is they have to wait like the rest of us - also because so much depends on funding rounds. Jannssen was a perfect example - from what I have gleaned post failure is that multiple staff inside Jannssen had expressed privately that the partnership was going to go to the next phase - then bang, it's over cause Jannssen changed direction.
What I do like is that PYC is treating Genentech casually (now that they are handing over the data) on the current deal and getting on with other business. I heard/read somewhere that G are keeping the dialogue open in the oncology space too so maybe something happens there but I suspect PYC has bigger plans than Genetech in oncology.
On the mouse thing - does anyone know if this is just an expanded test on multiple mice direct into tumors ie just a more broadbased pretrial or is it actually a test of the targetting ability? I thought the latter would still be a year or 2 away.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)